Verastem has reported primary analysis data from the Phase II RAMP 201 trial, where the avutometinib combination showed an ORR of 31% ...

Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.

Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their ...